Lyell Immunopharma Analyst Ratings
Lyell Immunopharma Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/28/2023 | 118.34% | JP Morgan | $15 → $5 | Downgrades | Overweight → Neutral |
| 05/05/2023 | 293.01% | HC Wainwright & Co. | → $9 | Reiterates | → Buy |
| 03/02/2023 | 293.01% | HC Wainwright & Co. | $11 → $9 | Maintains | Buy |
| 01/24/2023 | 74.67% | Morgan Stanley | $7 → $4 | Maintains | Equal-Weight |
| 11/14/2022 | 205.68% | Morgan Stanley | $15 → $7 | Downgrades | Overweight → Equal-Weight |
| 11/11/2022 | — | Goldman Sachs | Downgrades | Buy → Neutral | |
| 10/17/2022 | 424.02% | HC Wainwright & Co. | → $12 | Initiates Coverage On | → Buy |
| 05/24/2022 | 424.02% | Goldman Sachs | $21 → $12 | Maintains | Buy |
| 03/31/2022 | 817.03% | Goldman Sachs | $31 → $21 | Maintains | Buy |
| 01/06/2022 | 773.36% | Morgan Stanley | $25 → $20 | Maintains | Overweight |
| 07/12/2021 | 991.7% | Morgan Stanley | → $25 | Initiates Coverage On | → Overweight |
| 07/12/2021 | 991.7% | B of A Securities | → $25 | Initiates Coverage On | → Buy |
| 07/12/2021 | 860.7% | JP Morgan | → $22 | Initiates Coverage On | → Overweight |
| 07/12/2021 | 1210.04% | Goldman Sachs | → $30 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 08/28/2023 | 118.34% | 摩根大通 | 15 美元 → 5 美元 | 降级 | 超重 → 中性 |
| 05/05/2023 | 293.01% | HC Wainwright & Co. | → 9 美元 | 重申 | → 购买 |
| 03/02/2023 | 293.01% | HC Wainwright & Co. | 11 美元 → 9 美元 | 维护 | 购买 |
| 01/24/2023 | 74.67% | 摩根士丹利 | 7 美元 → 4 美元 | 维护 | 重量相等 |
| 11/14/2022 | 205.68% | 摩根士丹利 | 15 美元 → 7 美元 | 降级 | 超重 → 重量相等 |
| 11/11/2022 | — | 高盛 | 降级 | 买入 → 中性 | |
| 2022 年 10 月 17 日 | 424.02% | HC Wainwright & Co. | → 12 美元 | 启动覆盖开启 | → 购买 |
| 2022 年 5 月 24 日 | 424.02% | 高盛 | 21 美元 → 12 美元 | 维护 | 购买 |
| 03/31/2022 | 817.03% | 高盛 | 31 美元 → 21 美元 | 维护 | 购买 |
| 01/06/2022 | 773.36% | 摩根士丹利 | 25 美元 → 20 美元 | 维护 | 超重 |
| 2021 年 12 月 7 日 | 991.7% | 摩根士丹利 | → 25 美元 | 启动覆盖开启 | → 超重 |
| 2021 年 12 月 7 日 | 991.7% | B of A 类证券 | → 25 美元 | 启动覆盖开启 | → 购买 |
| 2021 年 12 月 7 日 | 860.7% | 摩根大通 | → 22 美元 | 启动覆盖开启 | → 超重 |
| 2021 年 12 月 7 日 | 1210.04% | 高盛 | → 30 美元 | 启动覆盖开启 | → 购买 |
What is the target price for Lyell Immunopharma (LYEL)?
Lyell Immunopharma（LYEL）的目标价格是多少？
The latest price target for Lyell Immunopharma (NASDAQ: LYEL) was reported by JP Morgan on August 28, 2023. The analyst firm set a price target for $5.00 expecting LYEL to rise to within 12 months (a possible 118.34% upside). 7 analyst firms have reported ratings in the last year.
摩根大通于2023年8月28日公布了Lyell Immunopharma（纳斯达克股票代码：LYEL）的最新目标股价。该分析公司将目标股价定为5.00美元，预计LYEL将在12个月内上涨至118.34％（可能上涨118.34％）。去年有7家分析公司公布了评级。
What is the most recent analyst rating for Lyell Immunopharma (LYEL)?
Lyell Immunopharma（LYEL）的最新分析师评级是多少？
The latest analyst rating for Lyell Immunopharma (NASDAQ: LYEL) was provided by JP Morgan, and Lyell Immunopharma downgraded their neutral rating.
摩根大通提供了Lyell Immunopharma（纳斯达克股票代码：LYEL）的最新分析师评级，Lyell Immunopharma下调了中性评级。
When is the next analyst rating going to be posted or updated for Lyell Immunopharma (LYEL)?
Lyell Immunopharma（LYEL）的下一次分析师评级何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Lyell Immunopharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Lyell Immunopharma was filed on August 28, 2023 so you should expect the next rating to be made available sometime around August 28, 2024.
分析师在进行了广泛的研究后得出了股票评级，包括阅读公开财务报表、与Lyell Immunopharma的高管和客户交谈以及听取财报电话会议。大多数分析师每三个月进行一次评级，因此每家公司每年应获得4个评级。Lyell Immunopharma的最后一次评级是在2023年8月28日提交的，因此你应该预计下一个评级将在2024年8月28日左右公布。
Is the Analyst Rating Lyell Immunopharma (LYEL) correct?
分析师对 Lyell Immunopharma（LYEL）的评级是否正确？
While ratings are subjective and will change, the latest Lyell Immunopharma (LYEL) rating was a downgraded with a price target of $15.00 to $5.00. The current price Lyell Immunopharma (LYEL) is trading at is $2.29, which is out of the analyst's predicted range.
尽管评级是主观的，并且会发生变化，但最新的Lyell Immunopharma（LYEL）评级被下调，目标股价为15.00美元至5.00美元。Lyell Immunopharma（LYEL）目前的交易价格为2.29美元，超出了分析师的预期区间。
译文内容由第三方软件翻译。